Clinical Trial News and Research

RSS

Cardiologist receives grant to study impact of erectile dysfunction drugs on muscular dystrophy patients

A Cedars-Sinai Heart Institute cardiologist has been awarded a three-year, nearly $1 million grant from the Muscular Dystrophy Association (MDA) to study whether drugs used to treat erectile dysfunction could also be used to improve muscle blood flow and reduce fatigue in muscular dystrophy patients.

25 Mar 2010

Xifaxan drug receives FDA approval

The U.S. Food and Drug Administration today approved the use of Xifaxan for reduction in the risk of the recurrence of overt hepatic encephalopathy (HE) in patients with advanced liver disease.

25 Mar 2010

InvestorSoup.com announces investment report featuring Oncothyreon

InvestorSoup.com announces an investment report featuring Oncothyreon Inc. (Nasdaq:ONTY). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

24 Mar 2010

Virtual biopsy probes to detect precancerous polyps to be available soon

The newest generation of "virtual biopsy" colonoscopy probes being tested at the Mayo Clinic campus in Florida demonstrate that it might soon be possible to use such a device to determine whether a colon polyp is benign and not remove it for biopsy. Currently, all colon polyps are extracted during a colonoscopy and sent to a pathologist for examination, which adds time, expense, and some surgical risk, to the procedure.

24 Mar 2010

New software may help improve safety among senior drivers

Psychologists at the University of Alabama at Birmingham (UAB) Center for Research in Applied Gerontology are testing software to determine if it could help senior adult drivers avoid car crashes by improving their reflexes and reaction time

24 Mar 2010

Nabi Biopharmaceuticals expands share repurchase program to enhance shareholder value

Nabi Biopharmaceuticals announced today that its Board of Directors has approved an aggregate total of up to $60.9 million to repurchase the Company's outstanding common shares in the open market or in privately negotiated transactions.

24 Mar 2010

Renowned leaders to discuss latest findings in early-stage drug development for cancer

When people think of cancer treatment, chemotherapy infusions, injections and pills often come to mind. These treatments result from extensive research and testing in drug development. But how does the process begin?

24 Mar 2010

Children with neurofibromatosis more likely to have cardiovascular problems

Researchers have discovered how a genetic disease known mainly for its life-threatening tumors also can cause sudden death from cardiovascular disease in children, and are mounting a clinical trial to develop treatments for the problem.

24 Mar 2010

Garnet BioTherapeutics commences treatment in GBT009 trial for incisional wounds following breast reconstruction surgery

Garnet BioTherapeutics, Inc., a regenerative medicine company focused on developing cell based therapies, today announced that the first patient has been treated in a Phase 2 multicenter, double-blind, placebo-controlled study of its lead product candidate GBT009 at Unity Hospital in Rochester, New York. GBT009 gives off a variety of pro-regenerative growth factors and cytokines which help repair damaged tissue and reduce inflammation, ultimately augmenting the body's ability to heal itself.

23 Mar 2010

Merck Serono, EMD Serono suspend global clinical development program for Stimuvax temporarily

Oncothyreon Inc. today announced that Merck Serono, a division of Merck KGaA of Darmstadt, Germany, and its U.S. affiliate, EMD Serono, Inc., have temporarily suspended the worldwide clinical development program for Stimuvax(R) (BLP25 liposomal vaccine). The suspension is the result of a suspected unexpected serious adverse reaction in a patient with multiple myeloma participating in an exploratory clinical trial.

23 Mar 2010

Celladon Corporation receives USPTO notice of allowance covering MYDICAR for advanced heart failure

Celladon Corp. announced today that the United States Patent and Trademark Office (USPTO) has granted a notice of allowance for a broad patent covering the company's lead drug candidate MYDICAR®, a genetically targeted enzyme replacement therapy for advanced heart failure. The patent will be issued to The Regents of the University of California and licensed exclusively to Celladon.

23 Mar 2010

Merix Pharmaceutical introduces new Fast-Results! Genital Herpes Treatment

Merix Pharmaceutical Corp. unveiled its new Fast-Results!™ Genital Herpes Treatment March 1st while attending a retail industry trade show in Dallas. The first ever OTC treatment for genital herpes, Fast-Results! answers the unmet need of people who suffer painful symptoms caused by the herpes virus.

23 Mar 2010

Inhibitex announces net loss of $4.7M for fourth-quarter 2009

Inhibitex, Inc. today announced its financial results for the fourth quarter and year ended December 31, 2009 and provided an update on various corporate developments.

23 Mar 2010

Investment report on Arrowhead Research

BeaconEquity.com announces an investment report featuring Arrowhead Research Corp. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

23 Mar 2010

ChemGenex shares falter as FDA requests more data on new leukemia drug

ChemGenex Pharmaceuticals Ltd. Shares fell most in the last 16 years to AUD$0.44 following a concern raised by the US drug regulators – US FDA. The FDA requested on Monday for more uniform clinical test data before they review and consider approval of the company’s new leukemia drug.

23 Mar 2010

Ipsen, GTx expand partnership for toremifene 80 mg

Ipsen today announced the expansion of their partnership for the development and commercialization of toremifene 80 mg for the reduction of fractures in men with advanced prostate cancer on androgen deprivation therapy (ADT) and toremifene 20 mg for the prevention of prostate cancer in high risk patients with High Grade Prostatic Intraepithelial Neoplasia lesions (HGPIN).

23 Mar 2010

FDA's ODAC voted to review T315I mutation prior to approval of OMAPRO

ChemGenex Pharmaceuticals Limited announced today that the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee voted 7-1 that a validated test to identify the T315I mutation should be reviewed by the FDA prior to approval of OMAPRO™ (omacetaxine mepesuccinate).

23 Mar 2010

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Can-Fite BioPharma Ltd, a biopharmaceutical company, traded on the TASE and developing anti- inflammatory and anti-cancer drugs, announced today the filing of a patent application, in conjunction with the United Stated National Institutes of Health (NIH), for the treatment of Uveitis with its A3 adenosine receptor ligands.

23 Mar 2010

$CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval$

CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval

Cell Therapeutics, Inc. announced today that the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee panel voted unanimously that clinical trial data was not adequate to support approval of pixantrone for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.

23 Mar 2010

Advaxis' ADXS11-001 Phase 1 study for cervix cancer failures: 13.3% of treated patients alive at over 3 years

Ongoing follow up of the surviving patients from the phase I study of ADXS11-001 for the treatment of cervix cancer failures conducted by Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has shown that two of fifteen treated patients or 13.3% are still alive 1,248 and 1,128 days after receiving their initial dose.

23 Mar 2010

Clinical Trial News and Research

Cardiologist receives grant to study impact of erectile dysfunction drugs on muscular dystrophy patients

Xifaxan drug receives FDA approval

InvestorSoup.com announces investment report featuring Oncothyreon

Virtual biopsy probes to detect precancerous polyps to be available soon

New software may help improve safety among senior drivers

Nabi Biopharmaceuticals expands share repurchase program to enhance shareholder value

Renowned leaders to discuss latest findings in early-stage drug development for cancer

Children with neurofibromatosis more likely to have cardiovascular problems

Garnet BioTherapeutics commences treatment in GBT009 trial for incisional wounds following breast reconstruction surgery

Merck Serono, EMD Serono suspend global clinical development program for Stimuvax temporarily

Celladon Corporation receives USPTO notice of allowance covering MYDICAR for advanced heart failure

Merix Pharmaceutical introduces new Fast-Results! Genital Herpes Treatment

Inhibitex announces net loss of $4.7M for fourth-quarter 2009

Investment report on Arrowhead Research

ChemGenex shares falter as FDA requests more data on new leukemia drug

Ipsen, GTx expand partnership for toremifene 80 mg

FDA's ODAC voted to review T315I mutation prior to approval of OMAPRO

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval

Advaxis' ADXS11-001 Phase 1 study for cervix cancer failures: 13.3% of treated patients alive at over 3 years

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News